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Abstract 
Background: ‘Flare phenomenon’ after initial luteinizing hormone-releasing hormone agonist administration is a 
widely approved concept in the treatment of prostate cancer. In most guidelines, concomitant therapy with anti-
androgens is recommended to prevent this flare phenomenon. However, there are few reports describing serum 
prostate-specific antigen transitions after hormonal therapy. Here, we present a case of a man who experienced the 
biochemical and clinical flare phenomenon despite prior anti-androgen use and who has detailed data.
Case presentation: A 70-year-old Asian man with metastatic prostate cancer (multiple bone) was referred to our 
hospital. He was treated with prior anti-androgens and luteinizing hormone-releasing hormone agonist. Regardless 
of prior use of anti-androgens, his low back pain caused by bone metastases was deteriorated and serum prostate-
specific antigen level was raised from 974.8 ng/mL to 2,555.5 ng/mL within 3 weeks. Then, his serum prostate specific 
antigen level started to decrease along with the pain. The nadir reached 1.0 ng/mL and remained for 6 months. 
Because the serum level of prostate-specific antigen then began to increase again, anti-androgen was discontinued 
for anti-androgen withdrawal syndrome. Then the serum level decreased again to less than 0.1 ng/mL. Until now, his 
serum prostate-specific antigen level has been maintained at less than 0.1 ng/mL for more than 30 months without 
any clinical progressions.
Conclusion: We present the case of a patient in whom a clinical flare caused by an leuteinizing hormone-releasing 
hormone agonist was not prevented by prior anti-androgen administration. In addition, the nadir level of prostate-
specific antigen when he received leuteinizing hormone-releasing hormone monotherapy was ten times lower than 
when he received concomitant therapy, and period of anti-androgen withdrawal syndrome was longer than usual. In 
this case, anti-androgen was probably not effective from the initial administration. Awareness of the possibility of inef-
fectiveness of anti-androgens is important in the treatment of symptomatic metastatic prostate cancer. Leuteinizing 
hormone-releasing hormone antagonist and surgical castration is a more reliable clinical approach for the prostate 
cancer patients with symptomatic metastatic disease.
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Background
Luteinizing hormone-releasing hormone (LH-RH) ago-
nists are the ‘standard of care’ in hormonal therapy for 
the patients with advanced prostate cancer because they 
avoid the physical and psychological discomfort associ-
ated with orchiectomy [1]. However, potent initial detri-
mental effects, called the ‘flare phenomenon’, in advanced 
disease is a main concern at the initial LH-RH adminis-
tration, and it includes increased bone pain, acute blad-
der outlet obstruction, obstructive renal failure and spinal 
cord compression [1–3]. The European Association of 
Urology guidelines recommend use of anti-androgens to 
prevent the clinical flare phenomenon [1]. However, in 
the clinical practice, the impact of the concomitant use 
of anti-androgen to avoid the clinical flare phenomenon, 
has practically been largely unknown. We report the case 
of a patient with metastatic prostate cancer who experi-
enced the LH-RH agonist clinical flare despite preceding 
administration of non-steroidal anti-androgen.
Case report
A 70-year-old Asian man was referred to our hospital for 
treatment of prostate cancer. His serum prostate-specific 
antigen (PSA) level was 974.8 ng/mL and trans-perineal 
prostatic biopsy revealed prostate cancer, with a Glea-
son score 5 +  4. A whole-body bone scintigraphy dem-
onstrated multiple bone metastases [extent of disease 
(EOD): 2] including the sacral bone (Fig.  1a). Magnetic 
Fig. 1 Imaging and the clinical schema of a symptomatic metastatic prostate cancer patient. a Initial bone scan images showing multiple bone 
metastases, which included the sacral bone (arrow). b Initial clinical schematic presentation with alteration of the serum prostate-specific antigen 
level. c Clinical schematic presentation of the whole process with alteration of the serum prostate-specific antigen level.
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resonance imaging (MRI) also indicated a metastasis at 
the same site, which was causing severe low back pain. 
The patient was hospitalized for pain control and started 
to undergo hormonal therapy. Prior administration of 
the non-steroidal anti-androgen, bicalutamide, was fol-
lowed by injection of the LHRH-agonist, leuprorelin, 
after 1  week. However, severe back pain continued to 
increase with increased PSA serum level (Fig.  1b). One 
week after bicalutamide administration, serum PSA 
level was elevated to 1,211.2  ng/mL, and to 1,443.8  ng/
mL after 2  weeks. Three weeks after leuprorelin injec-
tion and 4 weeks after bicalutamide administration, while 
serum testosterone level had already been suppressed to 
castration levels (0.34  ng/mL), the serum PSA reached 
a peak of 2,555.5 ng/mL (Fig. 1b). Thereafter, the serum 
PSA level decreased along with the patient’s back pain. 
The serum testosterone was completely suppressed to 
a level of 0.1  ng/mL and PSA nadir reached 1.0  ng/mL 
and remained at approximately 1  ng/mL for 6  months 
(Fig.  1c). The PSA serum level then began to increase 
again without elevation of testosterone and any clinical 
symptoms, including back pain. For the purpose of anti-
androgen withdrawal syndrome (AWS), bicalutamide 
was discontinued, and the serum PSA level decreased 
again to less than 0.1  ng/mL. The patient is currently 
undergoing LH-RH agonist monotherapy and his serum 
PSA level has been maintained at less than 0.1  ng/mL 
for more than 30 months without any clinical symptoms 
(Fig. 1c).
Conclusion
We present the case of a patient in whom a clinical flare 
caused by an LH-RH agonist was not prevented by prior 
anti-androgen administration. In addition, this case dem-
onstrated a prolonged progression free survival (PFS) 
period (more than 30  months and continuing) of anti-
androgen withdrawal syndrome. Interestingly, the serum 
PSA nadir (0.1 ng/mL) during LH-RH agonist monother-
apy was 10-times less than the serum PSA level (1.0 ng/
mL) during concomitant anti-androgen and LH-RH ago-
nist administration.
Although LH-RH antagonists are available, the most 
common form of hormonal treatment is LH-RH agonist 
therapy. However, during the initial 1–2  weeks, a bio-
chemical and occasionally a clinical flare can occur [1–
3]. To prevent the flare-up phenomenon, it is generally 
thought that prior anti-androgen administration can pre-
vent the biochemical and clinical flare [1–3]. However, 
in the CS21 phase III Degarelix clinical trial, a smaller 
PSA surge was noted in the leuprolide patients, even 
those who were receiving concomitant anti-androgens 
[4]. In this trial, the authors cautioned that addition of 
an anti-androgen to a LH-RH antagonist does not always 
prevent the flare [4]. Oh et al. recently reported that the 
rates of clinical flare, including fractures, spinal cord 
compression, bladder outlet obstruction and narcotic 
prescriptions, were rare in the first 30  days after begin-
ning LH-RH agonist therapy regardless of whether or not 
anti-androgens are used [5]. In this study, they described 
their question as: “Does oral anti-androgen use before 
LH-RH agonists in patients with metastatic prostate can-
cer prevent clinical consequences of a testosterone flare?” 
[5]. Therefore, we present a valuable case here.
Anti-androgen withdrawal syndrome is also impor-
tant to discuss. Anti-androgen withdrawal syndrome 
was described for the first time by Scher and Kelly [6]. 
It is known that approximately one-third of patients 
respond to anti-androgen withdrawal for a median dura-
tion of 4 months [1, 6, 7]. In the SWOG 9426 trial, it was 
reported that the median PFS was 3 months [7]. In addi-
tion, 19% patients had a PFS of 12  months or greater, 
although all of these patients did not have metastatic 
disease (M0) [7]. In this study, factors associated with 
increased PFS and overall survival (OS) were longer 
period of anti-androgen use (more than 10  months), 
lower PSA at baseline (less than 10  ng/mL) and non-
metastatic disease [7]. In our case, the patient’s initial 
PSA is 974.8 ng/ml, the period of anti-androgen use was 
12  months and the patient had multiple bone metasta-
ses. Only one of these factors applied somewhat to our 
patient. However, in our patient, the withdrawal state 
continued for more than 30 months. In addition, the PSA 
serum nadir level during the concomitant anti-androgen 
administration is 10-times more than the level observed 
during LH-RH agonist monotherapy. Although no study 
has compared the PSA level nadir during the concomi-
tant administration of anti-androgens and during LH-RH 
agonist monotherapy, our case shows a prolonged period 
of AWS and failure to prevent the flare-up. This suggests 
that, in this case, bicalutamide was ineffective from the 
first administration.
In conclusion, we reported the case of a patient whose 
clinical flare could not be prevented or reduced by prior 
use of the anti-androgen, bicalutamide. With this valu-
able experience, we re-confirmed that an LH-RH antag-
onist and surgical castration is a more reliable clinical 
approach for the prostate cancer patients with sympto-
matic metastatic disease.
Consent
Written informed consent was obtained from the patient 
of this Case report and any accompanying images. A copy 
of the written consent is available for review by the Editor 
of this journal.
Page 4 of 4Uehara et al. BMC Res Notes  (2015) 8:335 
Abbreviations
LH-RH: luteinizing hormone-releasing hormone; PSA: prostate specific anti-
gen; AWS: anti-androgen withdrawal syndrome; EOD: extent of disease; PFS: 
progression free survival.
Authors’ contributions
SU planned and carried out the patient’s treatment, and drafted the manu-
script. YT participated in the patient’s treatment and helped to draft the 
manuscript. YF, AY, SY, SM, IF, and JY participated in the patient’s treatment 
and advised to draft the manuscript. All authors read and approved the final 
manuscript.
Acknowledgements
This work was partly supported by the Smoking Research Foundation and 
Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, 
Sports, Science and Technology, Japan.
Compliance with ethical guidelines
Competing interests
T Yuasa received remuneration for a lecture from Pfizer Japan (Tokyo, Japan) 
and Novartis Pharma Japan (Tokyo, Japan). The others authors declare that 
they have no competing interests.
Received: 9 March 2015   Accepted: 22 July 2015
References
 1. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast 
T et al (2014) EAU guidelines on prostate cancer. Part II: treatment of 
advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 
65(2):467–479
 2. Kuhn JM, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P et al (1989) 
Prevention of the transient adverse effects of a gonadotropin-releasing 
hormone analogue (buserelin) in metastatic prostatic carcinoma 
by administration of an antiandrogen (nilutamide). N Engl J Med 
321(7):413–418
 3. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr 
FA et al (1989) A controlled trial of leuprolide with and without flutamide 
in prostatic carcinoma. N Engl J Med 321(7):419–424
 4. Boccon-Gibod L, van der Meulen E, Persson BE (2011) An update on the 
use of gonadotropin-releasing hormone antagonists in prostate cancer. 
Ther Adv Urol. 3(3):127–140
 5. Oh WK, Landrum MB, Lamont EB, McNeil BJ, Keating NL (2010) Does 
oral antiandrogen use before leuteinizing hormone-releasing hormone 
therapy in patients with metastatic prostate cancer prevent clinical 
consequences of a testosterone flare? Urology. 75(3):642–647
 6. Scher HI, Kelly WK (1993) Flutamide withdrawal syndrome: its impact 
on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 
11(8):1566–1572
 7. Sartor AO, Tangen CM, Hussain MH, Eisenberger MA, Parab M, Fontana 
JA et al (2008) Southwest Oncology Group: antiandrogen withdrawal in 
castrate-refractory prostate cancer: a Southwest Oncology Group trial 
(SWOG 9426). Cancer 112(11):2393–2400
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
